The relevance of biomarkers which include cell cycle regulators, pro-apoptotic , markers of angio genesis and proliferation marker cells have been found to be significant in cancer tumour cells.1 P53 has been part of these markers and plays a crucial role in maintaining the integrity of the cells. P53 is produced through tumour suppressor gene. The activation of p53 is initiated when the cells surrounding it are damaged or stressed. When activated the p53 proteins initiate cell cycle arrest and DNA repair. In other cases it cases cell death. Thus the critical aspect in understanding p53 is the gene expression in tumour formation and its role in cancer formation when subjected to different antibodies. Thus there is need to find out how p53 isoforms can be expressed and how this expression is affected by antibodies which are be linked to outcomes in clinical arena and its role in cancer patient treatment. 2 The objective is to determine the impact of KJC12 specificity on different p53 isoforms linked to cancer.
The functioning of the p53 isoforms pathway in cells is not well understood in cancers though avenues such as mutation process or interaction with proteins. Current knowledge has grabbled with question of linking p53 mutations state and cancer treatment protocols and expected clinical outcomes among cancer patients, this signify that the functioning of p53 cycle has not be well established. 3 P53 has been shown to express itself in not only 1 form but in 12 different isoforms which is linked to splicing, translation initiation and promotive usage.
Thus it is acknowledged that p53 isoform expression is associated with cancer prognosis, leading to the relationship which p53 mutation treatment process and cancer outcomes to be largely un understood. Its molecular mechanism is well established. In this experimental study, we analysed how the biological activities of p53 isoforms are impaired by specific antibodies.4 This seeks to establish how p53 isoforms is expressed on p53 pathway and how this impacts on cancer treatment and overall ageing process.
This experiment thus analyses the biological effects of the different inhibition of p53 isoforms, which can interact with specific antibody referred to as KJC12 at protein level expression in human tissues both in cancer and normal tissues.
The first experiment analysis entailed transfections of H1299 lung cancer cells being subjected to p53 isoform expression. Transfections of p53 proteins (DNA), in H1299 cells which are human non small cell lung carcinoma cells derived from lymph node. H1299 cells have the ability to divide indefinitely. They have homozygous properties on TP53 cells which results in partial deletion, thus in this way do not express tumour suppressor of p53 isoforms which are responsible for effects on proliferation propensity. The extraction of protein was done after 24 hours after the transfection process and analysis done using 10% SDG PAGE , then immune blotting performed on two membranes having two antibodies, DO1 and the new established KJC12 antibody performed p53 isoform expression.
The results above shows that anti body DO1 only express three forms of p53; p53γ,p53β and p53α while the new antibody KJC12 is able to express 10 p53 isoforms when blotted, p53α p53β; Δ40p53α ,Δ133p53α, Δ133p53 α, Δ40p53β;p53γ and Δ160p53 β.
The results show that the new antibody KJC12 has the capacity to express p53 isoforms on the human lunge cells. It is able to express 10 proteins forms of the lung cancer thus creating the path way for the tumor cells compared to the DO1 which express only two forms of p53 isoforms in the cancer tissue.
The second experiment analyzed blood samples of four patients having Chronic Lymphocytic Leukemia. The testing was done twice the first day and fourth day. The tissue samples from contra lateral breast resection, both protein lystates were analyzed using 10%SDS PAGE then blotted on p53 antibodies.
The results above shows that KJC12 antibody can express p53 isoforms among the four patients effectively compared to the DO1 antibody, which it expresses only one p53 isoforms. From the cancer tissues, none of the DO1 antibody and the control KU 80 was not able to expresses any p53 isoforms compared to KJC12 which is able to express Δ133p53β and Δ40p53β p53 isoforms. This shows how the antibody can be specific to express the cancer gene on p53 isoforms; this can be crucial in linking treatment assessment and clinical outcomes for cancer patients.
Lastly analysis was done on colon cancer cells, HCT 116 cells were transfected on siRNA with distinct p53 isoforms which reduced the expression. The immune blotting was further extracted after 96 hours then analyzed on protein lysates having 10%SDS-PAGE, then immune blotting performed on p53 antibodies KJC12. The markers were expressed and KU 80 was used as a loading control. Then finally cell confluence was performed which calculations were performed using live cell imaging process.
Transfection was done using siRNA on the p53 isoforms in order to focus on gene expressions in large scale. This enables intracellular transfer of cells into the cells which enable them to be silenced. This transfection on the cell confluence enables the p53 isoforms to be expressed in small scale thus allowing accurate analysis of the isoforms.
The results above show that gene expression is exorbitant on KJC12 antibodies compared to all the other antibodies which display no gene expression. Further when cell confluence was monitored on the siRNA transfection, large exoneration was observed after 96 hours showing all components of p53 have been expressed.
This shows that time factor is crucial in gene expression when KJC12 antibody is used, it influence gene expression of p53 isoforms. All forms of gene expression have been expressed after 96 hours of cell confluence.
The expression of TP53 gene has been shown to display different isoforms which are responsible for splicity of schema of the human gene structure of p 53. The role of p53 isoforms on cancer formation and prognosis is crucial in understanding the growth and progression of cancer cells; it shows the correlation of the p53 isoforms gene expressions at the mRNA level of proteins. 5 From the results collected above shows that the specific expressions of p53 are linked to clinical response of cancer cells. When the new antibody KJC12 is analyzed on the p53 isoforms, the gene markers are able to express themselves and show the different types of isoforms present, thus allowing for clinical management of the cancer cells in the tissues.6
The data obtained in this lab experiments supports the evidence on the usage of KJC12 antibody in studying gene expression associated with cancer compared to other antibodies which has limited gene expression.KJC12 has definite specify on p53 isoforms thus able to detect the genes associated with cancer.
This understanding of the functioning of KJC12 is crucial in monitoring the p53 isoforms at the mRNA level, which changes significantly the landscape of cancer diagnosis using this antibody component. This result shows the novel revelation of how the new antibody can be able to express many p53 isoforms linked to cancer formation in humans. 7
Future work needs to focus on the various forms of p53 to seek an understanding on cancer development and its progression, which will yield innovation of providing novel targets aimed at establishing effecting cancer therapies and tumor markers to target on the p53 isoforms. Thus this shall be answering on which forms of specific isoforms can be targeted by specific cancer therapy.
To conclude it is evident that the p53 pathway on cancer cells can be well established with the use of KJC12 antibody and most of its isoforms expressed. This enables clinical assessments outcome on cancer prognosis to be linked on treatment and clinical outcomes. This antibody gives a breakthrough in understanding the previous inconsistence associated with p53 mutation, response and clinical outcomes in cancer treatment. The p53 gene expression entails the biological activities of cell cycle arrests and apoptosis through gene manipulation. Thus the antibody is effective in ensuring that molecular mechanism of p53 isoforms can be established and isolated this allowing gene therapy to remove the marker genes of cancer.
Reference
Essay Writing Service Features
Our Experience
No matter how complex your assignment is, we can find the right professional for your specific task. Contact Essay is an essay writing company that hires only the smartest minds to help you with your projects. Our expertise allows us to provide students with high-quality academic writing, editing & proofreading services.
Free Features
Free revision policy
$10Free bibliography & reference
$8Free title page
$8Free formatting
$8How Our Essay Writing Service Works
First, you will need to complete an order form. It's not difficult but, in case there is anything you find not to be clear, you may always call us so that we can guide you through it. On the order form, you will need to include some basic information concerning your order: subject, topic, number of pages, etc. We also encourage our clients to upload any relevant information or sources that will help.
Complete the order form
Once we have all the information and instructions that we need, we select the most suitable writer for your assignment. While everything seems to be clear, the writer, who has complete knowledge of the subject, may need clarification from you. It is at that point that you would receive a call or email from us.
Writer’s assignment
As soon as the writer has finished, it will be delivered both to the website and to your email address so that you will not miss it. If your deadline is close at hand, we will place a call to you to make sure that you receive the paper on time.
Completing the order and download